Global Pharma ADMET Testing 麻豆原创 Research Report 2025

Publication ID:

PB503253844

Publication Date:

March 4, 2025

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Medical Devices [2]

Pharma & Healthcare [3]

Description:

The global market for Pharma ADMET Testing was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Pharma ADMET Testing, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Pharma ADMET Testing.
The Pharma ADMET Testing market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Pharma ADMET Testing market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Pharma ADMET Testing companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
麻豆原创 Segmentation
By Company
CMIC Holdings
Charles River Laboratories
WuXi AppTec
Promega Corporation
Merck KGaA
Agilient Technologies
Biovia (Dassault Systemes)
Cyprotex Limited
Bio-Rad Laboratories
IQVIA
Segment by Type
In Vivo ADMET Testing
In Vitro ADMET Testing
Segment by Application
Systemic Toxicity Testing
Hepatotoxicity Testing
Renal Toxicity Testing
Neurotoxicity Testing
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Pharma ADMET Testing company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Pharma ADMET Testing 麻豆原创 Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 In Vivo ADMET Testing
1.2.3 In Vitro ADMET Testing
1.3 麻豆原创 by Application
1.3.1 Global Pharma ADMET Testing 麻豆原创 Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Systemic Toxicity Testing
1.3.3 Hepatotoxicity Testing
1.3.4 Renal Toxicity Testing
1.3.5 Neurotoxicity Testing
1.3.6 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Pharma ADMET Testing 麻豆原创 Perspective (2020-2031)
2.2 Global Pharma ADMET Testing Growth Trends by Region
2.2.1 Global Pharma ADMET Testing 麻豆原创 Size by Region: 2020 VS 2024 VS 2031
2.2.2 Pharma ADMET Testing Historic 麻豆原创 Size by Region (2020-2025)
2.2.3 Pharma ADMET Testing Forecasted 麻豆原创 Size by Region (2026-2031)
2.3 Pharma ADMET Testing 麻豆原创 Dynamics
2.3.1 Pharma ADMET Testing Industry Trends
2.3.2 Pharma ADMET Testing 麻豆原创 Drivers
2.3.3 Pharma ADMET Testing 麻豆原创 Challenges
2.3.4 Pharma ADMET Testing 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Pharma ADMET Testing Players by Revenue
3.1.1 Global Top Pharma ADMET Testing Players by Revenue (2020-2025)
3.1.2 Global Pharma ADMET Testing Revenue 麻豆原创 Share by Players (2020-2025)
3.2 Global Pharma ADMET Testing 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Pharma ADMET Testing Revenue
3.4 Global Pharma ADMET Testing 麻豆原创 Concentration Ratio
3.4.1 Global Pharma ADMET Testing 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Pharma ADMET Testing Revenue in 2024
3.5 Global Key Players of Pharma ADMET Testing Head office and Area Served
3.6 Global Key Players of Pharma ADMET Testing, Product and Application
3.7 Global Key Players of Pharma ADMET Testing, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Pharma ADMET Testing Breakdown Data by Type
4.1 Global Pharma ADMET Testing Historic 麻豆原创 Size by Type (2020-2025)
4.2 Global Pharma ADMET Testing Forecasted 麻豆原创 Size by Type (2026-2031)
5 Pharma ADMET Testing Breakdown Data by Application
5.1 Global Pharma ADMET Testing Historic 麻豆原创 Size by Application (2020-2025)
5.2 Global Pharma ADMET Testing Forecasted 麻豆原创 Size by Application (2026-2031)
6 North America
6.1 North America Pharma ADMET Testing 麻豆原创 Size (2020-2031)
6.2 North America Pharma ADMET Testing 麻豆原创 Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Pharma ADMET Testing 麻豆原创 Size by Country (2020-2025)
6.4 North America Pharma ADMET Testing 麻豆原创 Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Pharma ADMET Testing 麻豆原创 Size (2020-2031)
7.2 Europe Pharma ADMET Testing 麻豆原创 Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Pharma ADMET Testing 麻豆原创 Size by Country (2020-2025)
7.4 Europe Pharma ADMET Testing 麻豆原创 Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Pharma ADMET Testing 麻豆原创 Size (2020-2031)
8.2 Asia-Pacific Pharma ADMET Testing 麻豆原创 Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Pharma ADMET Testing 麻豆原创 Size by Region (2020-2025)
8.4 Asia-Pacific Pharma ADMET Testing 麻豆原创 Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Pharma ADMET Testing 麻豆原创 Size (2020-2031)
9.2 Latin America Pharma ADMET Testing 麻豆原创 Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Pharma ADMET Testing 麻豆原创 Size by Country (2020-2025)
9.4 Latin America Pharma ADMET Testing 麻豆原创 Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Pharma ADMET Testing 麻豆原创 Size (2020-2031)
10.2 Middle East & Africa Pharma ADMET Testing 麻豆原创 Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Pharma ADMET Testing 麻豆原创 Size by Country (2020-2025)
10.4 Middle East & Africa Pharma ADMET Testing 麻豆原创 Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 CMIC Holdings
11.1.1 CMIC Holdings Company Details
11.1.2 CMIC Holdings Business Overview
11.1.3 CMIC Holdings Pharma ADMET Testing Introduction
11.1.4 CMIC Holdings Revenue in Pharma ADMET Testing Business (2020-2025)
11.1.5 CMIC Holdings Recent Development
11.2 Charles River Laboratories
11.2.1 Charles River Laboratories Company Details
11.2.2 Charles River Laboratories Business Overview
11.2.3 Charles River Laboratories Pharma ADMET Testing Introduction
11.2.4 Charles River Laboratories Revenue in Pharma ADMET Testing Business (2020-2025)
11.2.5 Charles River Laboratories Recent Development
11.3 WuXi AppTec
11.3.1 WuXi AppTec Company Details
11.3.2 WuXi AppTec Business Overview
11.3.3 WuXi AppTec Pharma ADMET Testing Introduction
11.3.4 WuXi AppTec Revenue in Pharma ADMET Testing Business (2020-2025)
11.3.5 WuXi AppTec Recent Development
11.4 Promega Corporation
11.4.1 Promega Corporation Company Details
11.4.2 Promega Corporation Business Overview
11.4.3 Promega Corporation Pharma ADMET Testing Introduction
11.4.4 Promega Corporation Revenue in Pharma ADMET Testing Business (2020-2025)
11.4.5 Promega Corporation Recent Development
11.5 Merck KGaA
11.5.1 Merck KGaA Company Details
11.5.2 Merck KGaA Business Overview
11.5.3 Merck KGaA Pharma ADMET Testing Introduction
11.5.4 Merck KGaA Revenue in Pharma ADMET Testing Business (2020-2025)
11.5.5 Merck KGaA Recent Development
11.6 Agilient Technologies
11.6.1 Agilient Technologies Company Details
11.6.2 Agilient Technologies Business Overview
11.6.3 Agilient Technologies Pharma ADMET Testing Introduction
11.6.4 Agilient Technologies Revenue in Pharma ADMET Testing Business (2020-2025)
11.6.5 Agilient Technologies Recent Development
11.7 Biovia (Dassault Systemes)
11.7.1 Biovia (Dassault Systemes) Company Details
11.7.2 Biovia (Dassault Systemes) Business Overview
11.7.3 Biovia (Dassault Systemes) Pharma ADMET Testing Introduction
11.7.4 Biovia (Dassault Systemes) Revenue in Pharma ADMET Testing Business (2020-2025)
11.7.5 Biovia (Dassault Systemes) Recent Development
11.8 Cyprotex Limited
11.8.1 Cyprotex Limited Company Details
11.8.2 Cyprotex Limited Business Overview
11.8.3 Cyprotex Limited Pharma ADMET Testing Introduction
11.8.4 Cyprotex Limited Revenue in Pharma ADMET Testing Business (2020-2025)
11.8.5 Cyprotex Limited Recent Development
11.9 Bio-Rad Laboratories
11.9.1 Bio-Rad Laboratories Company Details
11.9.2 Bio-Rad Laboratories Business Overview
11.9.3 Bio-Rad Laboratories Pharma ADMET Testing Introduction
11.9.4 Bio-Rad Laboratories Revenue in Pharma ADMET Testing Business (2020-2025)
11.9.5 Bio-Rad Laboratories Recent Development
11.10 IQVIA
11.10.1 IQVIA Company Details
11.10.2 IQVIA Business Overview
11.10.3 IQVIA Pharma ADMET Testing Introduction
11.10.4 IQVIA Revenue in Pharma ADMET Testing Business (2020-2025)
11.10.5 IQVIA Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 麻豆原创 Size Estimation
13.1.1.3 麻豆原创 Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer

Companies Mentioned:

CMIC Holdings
Charles River Laboratories
WuXi AppTec
Promega Corporation
Merck KGaA
Agilient Technologies
Biovia (Dassault Systemes)
Cyprotex Limited
Bio-Rad Laboratories
IQVIA

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.